References of "Osteoporosis International"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures
Ethgen, Olivier ULg; Hiligsmann, Mickaël; Burlet, Nansa et al

in Osteoporosis International (2016), 27

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of ... [more ▼]

Summary: Titrated supplementations with vitamin D-fortified yogurt, based on spontaneous calcium and vitamin D intakes, can be cost-effective in postmenopausal women with or without increased risk of osteoporotic fractures. Introduction: The objective of this study is to assess the costeffectiveness of the vitamin D-fortified yogurt given to women with and without an increased risk of osteoporotic fracture. Methods: Avalidated cost-effectiveness microsimulation Markov model of osteoporosis management was used. Three personalized supplementation scenarios to reflect the Ca/Vit D needs taking into account the well-known variations in dietary habits and a possible pharmacological supplementation in Ca/ Vit D, given above or in combination with anti-osteoporosis medications: one yogurt per day, i.e., 400 mg of Ca+200 IU of Vit D (scenario 1 U), two yogurts per day, i.e., 800 mg of Ca+ 400 IU of Vit D (scenario 2 U), or three yogurts per day, i.e., 1, 200 mg of Ca+600 IU of Vit D (scenario 3 U). Results: One yogurt is cost-effective in the general population above the age of 70 years and in all age groups in women with low bone mineral density (BMD) or prevalent vertebral fracture (PVF). The daily intake of two yogurts is cost-effective above 80 years in the general population and above 70 years in the two groups of women at increased risk of fractures. However, an intake of three yogurts per day is only cost-effective above 80 years old in the general population, as well as in women with low BMD or PVF. Conclusions: Our study is the first economic analysis supporting the cost-effectiveness of dairy products, fortified with vitamin D, in the armamentarium against osteoporotic fractures. [less ▲]

Detailed reference viewed: 13 (5 ULg)
Full Text
Peer Reviewed
See detailPhysical rehabilitation in musculoskeletal conditions: which method?
Bruyère, Olivier ULg

in Osteoporosis International (2015, March), 26(S1), 68

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailDairy products & Bone Health: Turning facts and beliefs into clinical practice
Bruyère, Olivier ULg

in Osteoporosis International (2015, March), 26(S1), 383

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailOcanacatib antifracture efficacy and saftey in postmenopausal women with osteoporosis: results from the phase III long-term adonacatib fracture trial (LOFT)
McClung, MR; Langdahl, B; Papapoulos, S et al

in Osteoporosis International (2015), 26(S1), 35-36

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailDenosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension
Papapoulos, S; Roux, C; Bone, HG et al

in Osteoporosis International (2015), 26(S1), 37-39

Detailed reference viewed: 128 (3 ULg)
Full Text
Peer Reviewed
See detailThe position of Strontium ranelate in today's management of osteoporosis
Reginster, Jean-Yves ULg; Brandi, ML; Cannata-Andia, J et al

in Osteoporosis International (2015), 26(S1), 39

Detailed reference viewed: 19 (3 ULg)
Full Text
Peer Reviewed
See detailCritical evaluation of promising markers for sarcopenia
CAVALIER, Etienne ULg; GADISSEUR, Romy ULg; GEBOES, Séverine ULg et al

in Osteoporosis International (2015), 26(S1), 49-50

Detailed reference viewed: 47 (10 ULg)
Full Text
Peer Reviewed
See detailFurther reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
FERRARI, S.; ADACHI, J.D.; LUPPUNER, K. et al

in Osteoporosis International (2015), 26

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in ... [more ▼]

Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4–7 versus years 1–3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. Introduction This study aimed to evaluate whether denosumab treatment continued beyond 3 years is associated with a further reduction in nonvertebral fracture rates. Methods Participants who completed the 3-year placebocontrolled Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were invited to participate in an open-label extension. The present analysis includes 4,074 postmenopausal women with osteoporosis (n=2,343 long-term; n=1,731 cross-over) who enrolled in the extension, missed ≤1 dose during their first 3 years of denosumab treatment, and continued into the fourth year of treatment. Comparison of nonvertebral fracture rates during years 1–3 of denosumab with that of the fourth year and with the rate during years 4–7 was evaluated. Results For the combined group, the nonvertebral fracture rate per 100 participant-years was 2.15 for the first 3 years of denosumab treatment (referent) and 1.36 in the fourth year (rate ratio [RR]=0.64; 95 % confidence interval (CI)=0.48 to 0.85, p=0.003). Comparable findings were observed in the groups separately and when nonvertebral fracture rates during years 1–3 were compared to years 4–7 in the longterm group (RR=0.79; 95 % CI=0.62 to 1.00, p=0.046). Fracture rate reductions in year 4 were most prominent in subjects with persisting low hip bone mineral density (BMD). Conclusions Denosumab treatment beyond 3 years was associated with a further reduction in nonvertebral fracture rate that persisted through 7 years of continuous denosumab administration. The degree to which denosumab further reduces nonvertebral fracture risk appears influenced by the hip bone density achieved with initial therapy [less ▲]

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailTrabecular bone score (TBS) as a new complementary appproach for osteoporosis evaluation in clinical practice
Harvey, NC; Binkley, N; Brandi, ML et al

in Osteoporosis International (2015), 26(S1), 60

Detailed reference viewed: 34 (1 ULg)
Full Text
Peer Reviewed
See detailCan we identify patients to be treated in osteoarthritis?
Arden, NK; Richette, P; Cooper, C et al

in Osteoporosis International (2015), 26(S1), 61-62

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of drugs to treat sarcopenia
Reginster, Jean-Yves ULg; Cooper, C; Rizzoli, R et al

in Osteoporosis International (2015), 26(S1), 62

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailClinical components linked to sarcopenia: the sarcophage study
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Petermans, Jean ULg et al

in Osteoporosis International (2015), 26(S1), 144

Detailed reference viewed: 48 (14 ULg)
Full Text
Peer Reviewed
See detailGrip fatigue resistance and self-perceived fatigue in relation with sarcopenia and quality of life
Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg; Bautmans, I et al

in Osteoporosis International (2015), 26(S1), 147-148

Detailed reference viewed: 24 (7 ULg)